RECRUITING

A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age

Description

The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.

Conditions

Respiratory Syncytial Virus
Talk to us

Related Conditions:

Respiratory Syncytial Virus

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.

A Phase 3 Open-label Study to Evaluate Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 at Least 12 Months Following a Primary Dose of a Licensed Protein Subunit RSV Vaccine in Adult Participants ≥60 Years of Age

A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age

Condition
Respiratory Syncytial Virus
Intervention / Treatment

-

Contacts and Locations

Denver

Velocity Clinical Research, Denver, Denver, Colorado, United States, 80110

Hialeah

Indago Research & Health Center, Inc., Hialeah, Florida, United States, 33012

Savannah

Velocity Clinical Research, Savannah, Savannah, Georgia, United States, 31406

Valparaiso

Velocity Clinical Research, Valparaiso, Valparaiso, Indiana, United States, 46383

Covington

Velocity Clinical Research, Covington, Covington, Louisiana, United States, 70433

Rockville

Velocity Clinical Research, Rockville, Rockville, Maryland, United States, 20854

Lincoln

Velocity Clinical Research, Lincoln, Lincoln, Nebraska, United States, 68510

Medford

Velocity Clinical Research, Medford, Medford, Oregon, United States, 97504

Austin

Velocity Clinical Research, Austin, Austin, Texas, United States, 78759

Hampton

Velocity Clinical Research, Hampton, Hampton, Virginia, United States, 23666

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participants may have one or more chronic medical diagnoses, but should be medically stable as assessed by:
  • * Absence of changes in medical therapy within 60 days of Visit 1 due to treatment failure or toxicity.
  • * Absence of serious or significant medical events within 30 days of Visit 1.
  • * Absence of known, current, and life-limiting diagnoses which, in the opinion of the Investigator, would make completion of the protocol unlikely.
  • * Participant has received a single dose of Arexvy or Abrysvo at least 12 months prior to Visit 1. Participants must provide proof of RSV vaccination status (including brand and date received) prior to enrollment.
  • * Participant has received or plans to receive any vaccine authorized or approved by a local health agency ≤14 days prior to study injection (Day 1) or plans to receive a vaccine authorized or approved by a local health agency within 14 days after the study injection. Nonstudy vaccination(s) should not be delayed.
  • * Prior participation in research involving receipt of any investigational RSV product (drug/biologic).
  • * Has received systemic immunoglobulins, long-acting biological therapies that affect immune responses (for example, infliximab) or blood products within 90 days prior to Visit 1 or plans to receive them during the study.

Ages Eligible for Study

60 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

ModernaTX, Inc.,

Study Record Dates

2026-04-15